| Literature DB >> 34670092 |
Gilbert S Omenn1,2, Lydie Lane3, Christopher M Overall4, Young-Ki Paik5, Ileana M Cristea6, Fernando J Corrales7, Cecilia Lindskog8, Susan Weintraub9, Michael H A Roehrl10, Siqi Liu11, Nuno Bandeira12, Sudhir Srivastava13, Yu-Ju Chen14, Ruedi Aebersold15, Robert L Moritz2, Eric W Deutsch2.
Abstract
The 2021 Metrics of the HUPO Human Proteome Project (HPP) show that protein expression has now been credibly detected (neXtProt PE1 level) for 18 357 (92.8%) of the 19 778 predicted proteins coded in the human genome, a gain of 483 since 2020 from reports throughout the world reanalyzed by the HPP. Conversely, the number of neXtProt PE2, PE3, and PE4 missing proteins has been reduced by 478 to 1421. This represents remarkable progress on the proteome parts list. The utilization of proteomics in a broad array of biological and clinical studies likewise continues to expand with many important findings and effective integration with other omics platforms. We present highlights from the Immunopeptidomics, Glycoproteomics, Infectious Disease, Cardiovascular, Musculo-Skeletal, Liver, and Cancers B/D-HPP teams and from the Knowledgebase, Mass Spectrometry, Antibody Profiling, and Pathology resource pillars, as well as ethical considerations important to the clinical utilization of proteomics and protein biomarkers.Entities:
Keywords: Biology and Disease-HPP (B/D-HPP); Chromosome-centric HPP (C-HPP); Human Protein Atlas; Human Proteome Project (HPP); Mass Spectrometry Interactive Virtual Environment (MassIVE); PeptideAtlas; missing proteins (MP); neXtProt protein existence (PE) metrics; non-MS PE1 proteins; uncharacterized protein existence 1 (uPE1)
Mesh：
Substances：
Year: 2021 PMID： 34670092 PMCID： PMC9340669 DOI： 10.1021/acs.jproteome.1c00590
Source DB: PubMed Journal: J Proteome Res ISSN： 1535-3893 Impact factor: 5.370